Overview

Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors

Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, dose-finding, multi-centre, phase Ⅰb study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai JMT-Bio Inc.
Treatments:
Calcium
Calcium, Dietary
Vitamin D